Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study-Reference-Cited by-同舟云学术

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study

Published:2010-10-16 Issue:11 Volume:257 Page:1917-1923
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Anderson G.,Meyer D.,Herrman C. E.,Sheppard C.,Murray R.,Fox E. J.,Mathena J.,Conner J.,Buck P. O.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://www.springerlink.com/index/pdf/10.1007/s00415-010-5779-x

Reference14 articles.

1. (2009) Copaxone (Glatiramer acetate injection) prescribing information. Teva Pharmaceuticals USA, Inc, North Wales

2. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging––measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297

3. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS (2006) A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 12:309–320

4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276

5. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50:701–708

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design;Advanced Drug Delivery Reviews;2024-06

2. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design;Advanced Drug Delivery Reviews;2024-06

3. Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review;Advances in Therapy;2024-03-11

4. Novel liposomal glatiramer acetate: Preparation and immunomodulatory evaluation in murine model of multiple sclerosis;International Journal of Pharmaceutics;2023-12

5. A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar);Rheumatology and Therapy;2022-07-01